Vol. 43 (4): 579-583, July – August, 2017
doi: 10.1590/S1677-5538.IBJU.2017.04.02
DIFFERENCE OF OPINION
Paolo Dell’Oglio 1,2, Rafael Sanchez-Salas 1
1 Department of Urology, Institut Mutualiste Montsouris, Paris, France; 2 Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
Keywords: Prostatic Neoplasms; Patients; Epidemiology
INTRODUCTION
Localized prostate cancer (LPCa) is an heterogeneous disease extending from individuals who harbor indolent cancer, that are highly unlikely to develop metastases, to individuals with more aggressive disease, that have higher risk of metastatic burden. This would translates into different oncologic outcomes and have implications for disease management.
Once the diagnosis of LPCa is established, remains challenging to identify those patients who may benefit from delayed or immediate treatment. Several options exist, from active surveillance (AS) to the whole-gland treatments (1). However, the optimal one is still unclear. To date, the percentage distribution of treatment for LPCa is around 8.4% for observation, 13.1% for ablative therapies, 28.1% for external beam radiotherapy (RT), 1.6% for brachytherapy, 45% for radical prostatectomy (RP) and 3.7% for primary androgen deprivation therapy (2)…
